Total Funding
17
40
Total FundingPrivate Equity raised
Growth Score
-15 pts
Heat Score
-10 pts
Company Performance Metrics
Score
Trend
AI Content may contain mistakes and is not legal, financial or investment advice.Learn more.
Growth Score - The measure of growth based on company activity, operational metrics, and investments
Growth Trend - The change in the growth score over the given time period
Heat Score - The measure of the market interest, media activity, and Crunchbase profile activity
Heat Trend - The change in the heat score over the given time period
See more interactive data and historical milestones on desktop for the best experience
92593
GigaGen specialized in the early discovery and development of recombinant biotherapeutic medicines.
Acquired by 
Grifols
Jennifer Keller: Head of MarketingPast Role: Natera, Vice President, Medical Education and Clinical Affairs
Rena Mizrahi: Vice President of Process DevelopmentPast Role: GigaGen, Director of Protein Engineering
About the Company
GigaGen is advancing a pipeline of first-in-class biotherapeutics, including novel oncology antibody drug combinations and the world’s first recombinant polyclonal hyperimmune gammaglobulin. Behind our diverse and growing pipeline is a mission to bring forth a new generation of highly efficacious drugs, driven by an unparalleled understanding of
f immune dysregulation. Our proprietary antibody discovery technology quickly characterizes every cell in complex immune systems, powering our selection of drug targets, identification of drug candidates and preclinical assessment of efficacy.
